nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—CA6—saliva—hepatitis B	0.0167	0.0945	CbGeAlD
Nilotinib—ABCG2—Lamivudine—hepatitis B	0.014	0.735	CbGbCtD
Nilotinib—LYN—blood plasma—hepatitis B	0.00933	0.0528	CbGeAlD
Nilotinib—MAPK14—blood plasma—hepatitis B	0.00642	0.0364	CbGeAlD
Nilotinib—ABCB1—Lamivudine—hepatitis B	0.00505	0.265	CbGbCtD
Nilotinib—UGT1A1—blood plasma—hepatitis B	0.00503	0.0285	CbGeAlD
Nilotinib—BLK—blood—hepatitis B	0.00468	0.0265	CbGeAlD
Nilotinib—CSF1R—blood plasma—hepatitis B	0.00464	0.0263	CbGeAlD
Nilotinib—KIT—blood plasma—hepatitis B	0.00422	0.0239	CbGeAlD
Nilotinib—CA1—blood plasma—hepatitis B	0.00386	0.0219	CbGeAlD
Nilotinib—FRK—liver—hepatitis B	0.0038	0.0215	CbGeAlD
Nilotinib—MAPK8—blood—hepatitis B	0.0037	0.021	CbGeAlD
Nilotinib—Amylase increased—Lamivudine—hepatitis B	0.00342	0.00811	CcSEcCtD
Nilotinib—LYN—blood—hepatitis B	0.00342	0.0194	CbGeAlD
Nilotinib—Hyperkalaemia—Adefovir Dipivoxil—hepatitis B	0.00337	0.00799	CcSEcCtD
Nilotinib—MAP4K1—blood—hepatitis B	0.00337	0.0191	CbGeAlD
Nilotinib—Chest discomfort—Telbivudine—hepatitis B	0.00327	0.00774	CcSEcCtD
Nilotinib—Musculoskeletal stiffness—Telbivudine—hepatitis B	0.00322	0.00764	CcSEcCtD
Nilotinib—CDC42BPB—liver—hepatitis B	0.0032	0.0181	CbGeAlD
Nilotinib—BRAF—blood—hepatitis B	0.00308	0.0174	CbGeAlD
Nilotinib—Musculoskeletal pain—Telbivudine—hepatitis B	0.00292	0.00693	CcSEcCtD
Nilotinib—Neck pain—Telbivudine—hepatitis B	0.00292	0.00693	CcSEcCtD
Nilotinib—MAPK8—liver—hepatitis B	0.0029	0.0164	CbGeAlD
Nilotinib—Hepatic function abnormal—Adefovir Dipivoxil—hepatitis B	0.00285	0.00676	CcSEcCtD
Nilotinib—Hypertriglyceridaemia—Lamivudine—hepatitis B	0.00284	0.00672	CcSEcCtD
Nilotinib—Influenza like illness—Telbivudine—hepatitis B	0.00281	0.00665	CcSEcCtD
Nilotinib—HCK—blood—hepatitis B	0.00281	0.0159	CbGeAlD
Nilotinib—ABL2—blood—hepatitis B	0.00279	0.0158	CbGeAlD
Nilotinib—LYN—liver—hepatitis B	0.00267	0.0151	CbGeAlD
Nilotinib—Folliculitis—Lamivudine—hepatitis B	0.00259	0.00614	CcSEcCtD
Nilotinib—EPHA4—blood—hepatitis B	0.00255	0.0144	CbGeAlD
Nilotinib—TIE1—liver—hepatitis B	0.00251	0.0142	CbGeAlD
Nilotinib—Sepsis—Telbivudine—hepatitis B	0.00251	0.00595	CcSEcCtD
Nilotinib—CA2—blood plasma—hepatitis B	0.0025	0.0142	CbGeAlD
Nilotinib—Blood triglycerides increased—Lamivudine—hepatitis B	0.00249	0.00589	CcSEcCtD
Nilotinib—BRAF—liver—hepatitis B	0.00241	0.0136	CbGeAlD
Nilotinib—Blood creatinine increased—Entecavir—hepatitis B	0.00239	0.00567	CcSEcCtD
Nilotinib—CYP2C8—blood plasma—hepatitis B	0.00238	0.0135	CbGeAlD
Nilotinib—Blood creatine phosphokinase increased—Lamivudine—hepatitis B	0.00237	0.00561	CcSEcCtD
Nilotinib—MAPK14—blood—hepatitis B	0.00235	0.0133	CbGeAlD
Nilotinib—FGR—blood—hepatitis B	0.00234	0.0133	CbGeAlD
Nilotinib—LCK—blood—hepatitis B	0.00234	0.0133	CbGeAlD
Nilotinib—Blood creatinine increased—Adefovir Dipivoxil—hepatitis B	0.00233	0.00553	CcSEcCtD
Nilotinib—Abdominal pain upper—Entecavir—hepatitis B	0.00233	0.00553	CcSEcCtD
Nilotinib—Hepatomegaly—Lamivudine—hepatitis B	0.0023	0.00545	CcSEcCtD
Nilotinib—EPHB4—blood—hepatitis B	0.00223	0.0126	CbGeAlD
Nilotinib—Alanine aminotransferase increased—Adefovir Dipivoxil—hepatitis B	0.0022	0.00521	CcSEcCtD
Nilotinib—HCK—liver—hepatitis B	0.00219	0.0124	CbGeAlD
Nilotinib—EPHA2—blood—hepatitis B	0.00219	0.0124	CbGeAlD
Nilotinib—ABL2—liver—hepatitis B	0.00218	0.0124	CbGeAlD
Nilotinib—Pancreatitis—Entecavir—hepatitis B	0.00216	0.00513	CcSEcCtD
Nilotinib—CYP2B6—blood plasma—hepatitis B	0.00214	0.0121	CbGeAlD
Nilotinib—TEK—blood—hepatitis B	0.00213	0.0121	CbGeAlD
Nilotinib—CYP2C9—blood plasma—hepatitis B	0.00212	0.012	CbGeAlD
Nilotinib—Pancreatitis—Adefovir Dipivoxil—hepatitis B	0.00211	0.00501	CcSEcCtD
Nilotinib—Pain in extremity—Telbivudine—hepatitis B	0.0021	0.00497	CcSEcCtD
Nilotinib—Hyperaesthesia—Lamivudine—hepatitis B	0.00207	0.00492	CcSEcCtD
Nilotinib—Migraine—Telbivudine—hepatitis B	0.00206	0.0049	CcSEcCtD
Nilotinib—Neutropenia—Entecavir—hepatitis B	0.00206	0.00489	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Entecavir—hepatitis B	0.00205	0.00486	CcSEcCtD
Nilotinib—EPHB6—blood—hepatitis B	0.00204	0.0115	CbGeAlD
Nilotinib—Hyperglycaemia—Entecavir—hepatitis B	0.00199	0.00472	CcSEcCtD
Nilotinib—Dysphonia—Lamivudine—hepatitis B	0.00198	0.00469	CcSEcCtD
Nilotinib—CA3—liver—hepatitis B	0.00197	0.0112	CbGeAlD
Nilotinib—Weight decreased—Adefovir Dipivoxil—hepatitis B	0.00195	0.00462	CcSEcCtD
Nilotinib—Renal failure—Entecavir—hepatitis B	0.00193	0.00459	CcSEcCtD
Nilotinib—PDGFRA—blood—hepatitis B	0.00193	0.0109	CbGeAlD
Nilotinib—Abdominal pain upper—Telbivudine—hepatitis B	0.00192	0.00454	CcSEcCtD
Nilotinib—Aspartate aminotransferase increased—Telbivudine—hepatitis B	0.00189	0.00448	CcSEcCtD
Nilotinib—Renal failure—Adefovir Dipivoxil—hepatitis B	0.00189	0.00447	CcSEcCtD
Nilotinib—Haematuria—Entecavir—hepatitis B	0.00188	0.00445	CcSEcCtD
Nilotinib—Nasopharyngitis—Telbivudine—hepatitis B	0.00188	0.00445	CcSEcCtD
Nilotinib—Jaundice—Adefovir Dipivoxil—hepatitis B	0.00187	0.00444	CcSEcCtD
Nilotinib—Hepatobiliary disease—Entecavir—hepatitis B	0.00186	0.00441	CcSEcCtD
Nilotinib—Gastritis—Telbivudine—hepatitis B	0.00186	0.0044	CcSEcCtD
Nilotinib—Muscular weakness—Telbivudine—hepatitis B	0.00185	0.00439	CcSEcCtD
Nilotinib—Alanine aminotransferase increased—Telbivudine—hepatitis B	0.00185	0.00439	CcSEcCtD
Nilotinib—UGT1A1—blood—hepatitis B	0.00184	0.0104	CbGeAlD
Nilotinib—MAPK14—liver—hepatitis B	0.00184	0.0104	CbGeAlD
Nilotinib—LCK—liver—hepatitis B	0.00183	0.0104	CbGeAlD
Nilotinib—FGR—liver—hepatitis B	0.00183	0.0104	CbGeAlD
Nilotinib—Haematuria—Adefovir Dipivoxil—hepatitis B	0.00183	0.00434	CcSEcCtD
Nilotinib—Abdominal distension—Telbivudine—hepatitis B	0.00182	0.00433	CcSEcCtD
Nilotinib—Hepatobiliary disease—Adefovir Dipivoxil—hepatitis B	0.00182	0.0043	CcSEcCtD
Nilotinib—Influenza—Telbivudine—hepatitis B	0.00181	0.0043	CcSEcCtD
Nilotinib—Rectal haemorrhage—Lamivudine—hepatitis B	0.0018	0.00427	CcSEcCtD
Nilotinib—Oropharyngeal pain—Lamivudine—hepatitis B	0.00179	0.00425	CcSEcCtD
Nilotinib—CA14—liver—hepatitis B	0.00179	0.0101	CbGeAlD
Nilotinib—Hepatitis—Entecavir—hepatitis B	0.00177	0.00419	CcSEcCtD
Nilotinib—MAP2K5—blood—hepatitis B	0.00174	0.00988	CbGeAlD
Nilotinib—EPHB4—liver—hepatitis B	0.00174	0.00987	CbGeAlD
Nilotinib—Oedema peripheral—Entecavir—hepatitis B	0.00174	0.00413	CcSEcCtD
Nilotinib—Abdominal discomfort—Telbivudine—hepatitis B	0.00174	0.00412	CcSEcCtD
Nilotinib—Hepatitis—Adefovir Dipivoxil—hepatitis B	0.00172	0.00409	CcSEcCtD
Nilotinib—Hypercholesterolaemia—Lamivudine—hepatitis B	0.00172	0.00408	CcSEcCtD
Nilotinib—Hearing impaired—Lamivudine—hepatitis B	0.00171	0.00406	CcSEcCtD
Nilotinib—Pharyngitis—Adefovir Dipivoxil—hepatitis B	0.00171	0.00406	CcSEcCtD
Nilotinib—EPHA2—liver—hepatitis B	0.00171	0.00969	CbGeAlD
Nilotinib—Urinary tract disorder—Adefovir Dipivoxil—hepatitis B	0.0017	0.00404	CcSEcCtD
Nilotinib—CSF1R—blood—hepatitis B	0.0017	0.00964	CbGeAlD
Nilotinib—Neutropenia—Telbivudine—hepatitis B	0.0017	0.00402	CcSEcCtD
Nilotinib—Connective tissue disorder—Adefovir Dipivoxil—hepatitis B	0.00169	0.00402	CcSEcCtD
Nilotinib—Urethral disorder—Adefovir Dipivoxil—hepatitis B	0.00169	0.00401	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Telbivudine—hepatitis B	0.00168	0.00399	CcSEcCtD
Nilotinib—TEK—liver—hepatitis B	0.00167	0.00945	CbGeAlD
Nilotinib—Musculoskeletal pain—Lamivudine—hepatitis B	0.00165	0.00391	CcSEcCtD
Nilotinib—CYP3A4—blood plasma—hepatitis B	0.00161	0.00914	CbGeAlD
Nilotinib—Immune system disorder—Entecavir—hepatitis B	0.0016	0.00378	CcSEcCtD
Nilotinib—Renal failure—Telbivudine—hepatitis B	0.00159	0.00377	CcSEcCtD
Nilotinib—CYP2D6—blood plasma—hepatitis B	0.00159	0.00899	CbGeAlD
Nilotinib—Neuropathy peripheral—Telbivudine—hepatitis B	0.00158	0.00376	CcSEcCtD
Nilotinib—Wheezing—Lamivudine—hepatitis B	0.00158	0.00375	CcSEcCtD
Nilotinib—Alopecia—Entecavir—hepatitis B	0.00156	0.0037	CcSEcCtD
Nilotinib—Mental disorder—Entecavir—hepatitis B	0.00155	0.00367	CcSEcCtD
Nilotinib—KIT—blood—hepatitis B	0.00155	0.00875	CbGeAlD
Nilotinib—Malnutrition—Entecavir—hepatitis B	0.00154	0.00365	CcSEcCtD
Nilotinib—Photophobia—Lamivudine—hepatitis B	0.00153	0.00362	CcSEcCtD
Nilotinib—Hepatobiliary disease—Telbivudine—hepatitis B	0.00153	0.00362	CcSEcCtD
Nilotinib—PDGFRA—liver—hepatitis B	0.00151	0.00856	CbGeAlD
Nilotinib—PDGFRB—blood—hepatitis B	0.00151	0.00855	CbGeAlD
Nilotinib—Malnutrition—Adefovir Dipivoxil—hepatitis B	0.0015	0.00356	CcSEcCtD
Nilotinib—Flatulence—Adefovir Dipivoxil—hepatitis B	0.00148	0.00351	CcSEcCtD
Nilotinib—Mouth ulceration—Lamivudine—hepatitis B	0.00147	0.00349	CcSEcCtD
Nilotinib—Gynaecomastia—Lamivudine—hepatitis B	0.00146	0.00345	CcSEcCtD
Nilotinib—Back pain—Adefovir Dipivoxil—hepatitis B	0.00145	0.00344	CcSEcCtD
Nilotinib—Hepatitis—Telbivudine—hepatitis B	0.00145	0.00344	CcSEcCtD
Nilotinib—Hypoaesthesia—Telbivudine—hepatitis B	0.00144	0.00342	CcSEcCtD
Nilotinib—UGT1A1—liver—hepatitis B	0.00144	0.00817	CbGeAlD
Nilotinib—Pharyngitis—Telbivudine—hepatitis B	0.00144	0.00341	CcSEcCtD
Nilotinib—Connective tissue disorder—Telbivudine—hepatitis B	0.00143	0.00338	CcSEcCtD
Nilotinib—CA1—blood—hepatitis B	0.00141	0.008	CbGeAlD
Nilotinib—Sepsis—Lamivudine—hepatitis B	0.00141	0.00335	CcSEcCtD
Nilotinib—Anaemia—Adefovir Dipivoxil—hepatitis B	0.00139	0.00329	CcSEcCtD
Nilotinib—Leukopenia—Entecavir—hepatitis B	0.00138	0.00326	CcSEcCtD
Nilotinib—MAP2K5—liver—hepatitis B	0.00136	0.00772	CbGeAlD
Nilotinib—ABL1—blood—hepatitis B	0.00135	0.00762	CbGeAlD
Nilotinib—Gastroenteritis—Lamivudine—hepatitis B	0.00133	0.00316	CcSEcCtD
Nilotinib—CSF1R—liver—hepatitis B	0.00133	0.00754	CbGeAlD
Nilotinib—Deafness—Lamivudine—hepatitis B	0.00132	0.00313	CcSEcCtD
Nilotinib—Cough—Adefovir Dipivoxil—hepatitis B	0.00131	0.0031	CcSEcCtD
Nilotinib—Mediastinal disorder—Telbivudine—hepatitis B	0.00131	0.0031	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Entecavir—hepatitis B	0.0013	0.00308	CcSEcCtD
Nilotinib—Chest pain—Adefovir Dipivoxil—hepatitis B	0.00128	0.00303	CcSEcCtD
Nilotinib—Myalgia—Adefovir Dipivoxil—hepatitis B	0.00128	0.00303	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Adefovir Dipivoxil—hepatitis B	0.00127	0.00301	CcSEcCtD
Nilotinib—Malnutrition—Telbivudine—hepatitis B	0.00126	0.00299	CcSEcCtD
Nilotinib—Infection—Entecavir—hepatitis B	0.00125	0.00296	CcSEcCtD
Nilotinib—Dysgeusia—Telbivudine—hepatitis B	0.00124	0.00293	CcSEcCtD
Nilotinib—Nervous system disorder—Entecavir—hepatitis B	0.00123	0.00292	CcSEcCtD
Nilotinib—Back pain—Telbivudine—hepatitis B	0.00122	0.0029	CcSEcCtD
Nilotinib—Skin disorder—Entecavir—hepatitis B	0.00122	0.00289	CcSEcCtD
Nilotinib—Muscle spasms—Telbivudine—hepatitis B	0.00121	0.00288	CcSEcCtD
Nilotinib—Hypoglycaemia—Lamivudine—hepatitis B	0.00121	0.00287	CcSEcCtD
Nilotinib—KIT—liver—hepatitis B	0.00121	0.00684	CbGeAlD
Nilotinib—Nervous system disorder—Adefovir Dipivoxil—hepatitis B	0.0012	0.00285	CcSEcCtD
Nilotinib—Thrombocytopenia—Adefovir Dipivoxil—hepatitis B	0.0012	0.00284	CcSEcCtD
Nilotinib—Skin disorder—Adefovir Dipivoxil—hepatitis B	0.00119	0.00282	CcSEcCtD
Nilotinib—PDGFRB—liver—hepatitis B	0.00118	0.00668	CbGeAlD
Nilotinib—Ill-defined disorder—Telbivudine—hepatitis B	0.00117	0.00278	CcSEcCtD
Nilotinib—Anorexia—Adefovir Dipivoxil—hepatitis B	0.00117	0.00277	CcSEcCtD
Nilotinib—Migraine—Lamivudine—hepatitis B	0.00116	0.00276	CcSEcCtD
Nilotinib—ABCB1—blood plasma—hepatitis B	0.00114	0.00647	CbGeAlD
Nilotinib—Malaise—Telbivudine—hepatitis B	0.00114	0.0027	CcSEcCtD
Nilotinib—Insomnia—Entecavir—hepatitis B	0.00113	0.00269	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Adefovir Dipivoxil—hepatitis B	0.00112	0.00264	CcSEcCtD
Nilotinib—CA1—liver—hepatitis B	0.00111	0.00626	CbGeAlD
Nilotinib—Dyspepsia—Entecavir—hepatitis B	0.0011	0.00262	CcSEcCtD
Nilotinib—CA4—blood—hepatitis B	0.0011	0.00626	CbGeAlD
Nilotinib—Cough—Telbivudine—hepatitis B	0.0011	0.00261	CcSEcCtD
Nilotinib—Dehydration—Lamivudine—hepatitis B	0.0011	0.00261	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Entecavir—hepatitis B	0.00108	0.00257	CcSEcCtD
Nilotinib—Fatigue—Entecavir—hepatitis B	0.00108	0.00257	CcSEcCtD
Nilotinib—Abdominal pain upper—Lamivudine—hepatitis B	0.00108	0.00256	CcSEcCtD
Nilotinib—Dyspepsia—Adefovir Dipivoxil—hepatitis B	0.00108	0.00256	CcSEcCtD
Nilotinib—Chest pain—Telbivudine—hepatitis B	0.00108	0.00255	CcSEcCtD
Nilotinib—Myalgia—Telbivudine—hepatitis B	0.00108	0.00255	CcSEcCtD
Nilotinib—Arthralgia—Telbivudine—hepatitis B	0.00108	0.00255	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Telbivudine—hepatitis B	0.00107	0.00253	CcSEcCtD
Nilotinib—Aspartate aminotransferase increased—Lamivudine—hepatitis B	0.00106	0.00252	CcSEcCtD
Nilotinib—Decreased appetite—Adefovir Dipivoxil—hepatitis B	0.00106	0.00252	CcSEcCtD
Nilotinib—Discomfort—Telbivudine—hepatitis B	0.00106	0.00252	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Adefovir Dipivoxil—hepatitis B	0.00106	0.00251	CcSEcCtD
Nilotinib—Nasopharyngitis—Lamivudine—hepatitis B	0.00106	0.00251	CcSEcCtD
Nilotinib—ABL1—liver—hepatitis B	0.00105	0.00596	CbGeAlD
Nilotinib—Alanine aminotransferase increased—Lamivudine—hepatitis B	0.00104	0.00247	CcSEcCtD
Nilotinib—Muscular weakness—Lamivudine—hepatitis B	0.00104	0.00247	CcSEcCtD
Nilotinib—Abdominal distension—Lamivudine—hepatitis B	0.00103	0.00244	CcSEcCtD
Nilotinib—Gastrointestinal pain—Entecavir—hepatitis B	0.00103	0.00243	CcSEcCtD
Nilotinib—Influenza—Lamivudine—hepatitis B	0.00102	0.00242	CcSEcCtD
Nilotinib—Nervous system disorder—Telbivudine—hepatitis B	0.00101	0.0024	CcSEcCtD
Nilotinib—Thrombocytopenia—Telbivudine—hepatitis B	0.00101	0.00239	CcSEcCtD
Nilotinib—Pancreatitis—Lamivudine—hepatitis B	0.001	0.00237	CcSEcCtD
Nilotinib—Skin disorder—Telbivudine—hepatitis B	0.001	0.00237	CcSEcCtD
Nilotinib—Gastrointestinal pain—Adefovir Dipivoxil—hepatitis B	0.001	0.00237	CcSEcCtD
Nilotinib—Body temperature increased—Entecavir—hepatitis B	0.000992	0.00235	CcSEcCtD
Nilotinib—Abdominal pain—Entecavir—hepatitis B	0.000992	0.00235	CcSEcCtD
Nilotinib—Bronchitis—Lamivudine—hepatitis B	0.000983	0.00233	CcSEcCtD
Nilotinib—Abdominal discomfort—Lamivudine—hepatitis B	0.000979	0.00232	CcSEcCtD
Nilotinib—Pancytopenia—Lamivudine—hepatitis B	0.00097	0.0023	CcSEcCtD
Nilotinib—Body temperature increased—Adefovir Dipivoxil—hepatitis B	0.000968	0.00229	CcSEcCtD
Nilotinib—Abdominal pain—Adefovir Dipivoxil—hepatitis B	0.000968	0.00229	CcSEcCtD
Nilotinib—Neutropenia—Lamivudine—hepatitis B	0.000955	0.00227	CcSEcCtD
Nilotinib—Dysuria—Lamivudine—hepatitis B	0.000955	0.00227	CcSEcCtD
Nilotinib—Pollakiuria—Lamivudine—hepatitis B	0.000944	0.00224	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Telbivudine—hepatitis B	0.000939	0.00223	CcSEcCtD
Nilotinib—Insomnia—Telbivudine—hepatitis B	0.000932	0.00221	CcSEcCtD
Nilotinib—Paraesthesia—Telbivudine—hepatitis B	0.000926	0.00219	CcSEcCtD
Nilotinib—Hyperglycaemia—Lamivudine—hepatitis B	0.000922	0.00219	CcSEcCtD
Nilotinib—CA2—blood—hepatitis B	0.000916	0.00519	CbGeAlD
Nilotinib—Dyspepsia—Telbivudine—hepatitis B	0.000907	0.00215	CcSEcCtD
Nilotinib—Asthenia—Entecavir—hepatitis B	0.0009	0.00213	CcSEcCtD
Nilotinib—Renal failure—Lamivudine—hepatitis B	0.000895	0.00212	CcSEcCtD
Nilotinib—Neuropathy peripheral—Lamivudine—hepatitis B	0.000893	0.00212	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Telbivudine—hepatitis B	0.00089	0.00211	CcSEcCtD
Nilotinib—Fatigue—Telbivudine—hepatitis B	0.000889	0.00211	CcSEcCtD
Nilotinib—Jaundice—Lamivudine—hepatitis B	0.000888	0.00211	CcSEcCtD
Nilotinib—Stomatitis—Lamivudine—hepatitis B	0.000888	0.00211	CcSEcCtD
Nilotinib—Pain—Telbivudine—hepatitis B	0.000882	0.00209	CcSEcCtD
Nilotinib—Asthenia—Adefovir Dipivoxil—hepatitis B	0.000878	0.00208	CcSEcCtD
Nilotinib—CYP2C8—blood—hepatitis B	0.000872	0.00494	CbGeAlD
Nilotinib—Pruritus—Adefovir Dipivoxil—hepatitis B	0.000866	0.00205	CcSEcCtD
Nilotinib—Hepatobiliary disease—Lamivudine—hepatitis B	0.000861	0.00204	CcSEcCtD
Nilotinib—Epistaxis—Lamivudine—hepatitis B	0.000859	0.00204	CcSEcCtD
Nilotinib—Diarrhoea—Entecavir—hepatitis B	0.000859	0.00204	CcSEcCtD
Nilotinib—Feeling abnormal—Telbivudine—hepatitis B	0.000849	0.00201	CcSEcCtD
Nilotinib—ABCG2—blood—hepatitis B	0.000848	0.0048	CbGeAlD
Nilotinib—Gastrointestinal pain—Telbivudine—hepatitis B	0.000843	0.002	CcSEcCtD
Nilotinib—Diarrhoea—Adefovir Dipivoxil—hepatitis B	0.000838	0.00199	CcSEcCtD
Nilotinib—Dizziness—Entecavir—hepatitis B	0.00083	0.00197	CcSEcCtD
Nilotinib—Rhinitis—Lamivudine—hepatitis B	0.00082	0.00194	CcSEcCtD
Nilotinib—Hepatitis—Lamivudine—hepatitis B	0.000818	0.00194	CcSEcCtD
Nilotinib—Body temperature increased—Telbivudine—hepatitis B	0.000815	0.00193	CcSEcCtD
Nilotinib—Abdominal pain—Telbivudine—hepatitis B	0.000815	0.00193	CcSEcCtD
Nilotinib—Hypoaesthesia—Lamivudine—hepatitis B	0.000814	0.00193	CcSEcCtD
Nilotinib—Pharyngitis—Lamivudine—hepatitis B	0.000812	0.00192	CcSEcCtD
Nilotinib—Connective tissue disorder—Lamivudine—hepatitis B	0.000804	0.00191	CcSEcCtD
Nilotinib—Vomiting—Entecavir—hepatitis B	0.000798	0.00189	CcSEcCtD
Nilotinib—Rash—Entecavir—hepatitis B	0.000791	0.00188	CcSEcCtD
Nilotinib—Dermatitis—Entecavir—hepatitis B	0.00079	0.00187	CcSEcCtD
Nilotinib—Headache—Entecavir—hepatitis B	0.000786	0.00186	CcSEcCtD
Nilotinib—CYP2B6—blood—hepatitis B	0.000783	0.00443	CbGeAlD
Nilotinib—Vomiting—Adefovir Dipivoxil—hepatitis B	0.000778	0.00185	CcSEcCtD
Nilotinib—CYP2C9—blood—hepatitis B	0.000775	0.00439	CbGeAlD
Nilotinib—Erythema multiforme—Lamivudine—hepatitis B	0.000773	0.00183	CcSEcCtD
Nilotinib—Rash—Adefovir Dipivoxil—hepatitis B	0.000772	0.00183	CcSEcCtD
Nilotinib—Dermatitis—Adefovir Dipivoxil—hepatitis B	0.000771	0.00183	CcSEcCtD
Nilotinib—Headache—Adefovir Dipivoxil—hepatitis B	0.000767	0.00182	CcSEcCtD
Nilotinib—Nausea—Entecavir—hepatitis B	0.000745	0.00177	CcSEcCtD
Nilotinib—Asthenia—Telbivudine—hepatitis B	0.00074	0.00175	CcSEcCtD
Nilotinib—Immune system disorder—Lamivudine—hepatitis B	0.000739	0.00175	CcSEcCtD
Nilotinib—Mediastinal disorder—Lamivudine—hepatitis B	0.000737	0.00175	CcSEcCtD
Nilotinib—Chills—Lamivudine—hepatitis B	0.000734	0.00174	CcSEcCtD
Nilotinib—Pruritus—Telbivudine—hepatitis B	0.000729	0.00173	CcSEcCtD
Nilotinib—Nausea—Adefovir Dipivoxil—hepatitis B	0.000727	0.00172	CcSEcCtD
Nilotinib—Alopecia—Lamivudine—hepatitis B	0.000723	0.00171	CcSEcCtD
Nilotinib—CA2—liver—hepatitis B	0.000716	0.00406	CbGeAlD
Nilotinib—Malnutrition—Lamivudine—hepatitis B	0.000712	0.00169	CcSEcCtD
Nilotinib—Erythema—Lamivudine—hepatitis B	0.000712	0.00169	CcSEcCtD
Nilotinib—Diarrhoea—Telbivudine—hepatitis B	0.000705	0.00167	CcSEcCtD
Nilotinib—Flatulence—Lamivudine—hepatitis B	0.000701	0.00166	CcSEcCtD
Nilotinib—Dysgeusia—Lamivudine—hepatitis B	0.000697	0.00165	CcSEcCtD
Nilotinib—Back pain—Lamivudine—hepatitis B	0.000689	0.00163	CcSEcCtD
Nilotinib—Muscle spasms—Lamivudine—hepatitis B	0.000684	0.00162	CcSEcCtD
Nilotinib—CYP2C8—liver—hepatitis B	0.000682	0.00386	CbGeAlD
Nilotinib—Dizziness—Telbivudine—hepatitis B	0.000682	0.00162	CcSEcCtD
Nilotinib—Tremor—Lamivudine—hepatitis B	0.000667	0.00158	CcSEcCtD
Nilotinib—ABCG2—liver—hepatitis B	0.000663	0.00376	CbGeAlD
Nilotinib—Ill-defined disorder—Lamivudine—hepatitis B	0.00066	0.00157	CcSEcCtD
Nilotinib—Anaemia—Lamivudine—hepatitis B	0.000658	0.00156	CcSEcCtD
Nilotinib—Vomiting—Telbivudine—hepatitis B	0.000655	0.00155	CcSEcCtD
Nilotinib—Rash—Telbivudine—hepatitis B	0.00065	0.00154	CcSEcCtD
Nilotinib—Dermatitis—Telbivudine—hepatitis B	0.000649	0.00154	CcSEcCtD
Nilotinib—Headache—Telbivudine—hepatitis B	0.000646	0.00153	CcSEcCtD
Nilotinib—Malaise—Lamivudine—hepatitis B	0.000642	0.00152	CcSEcCtD
Nilotinib—Vertigo—Lamivudine—hepatitis B	0.00064	0.00152	CcSEcCtD
Nilotinib—Syncope—Lamivudine—hepatitis B	0.000638	0.00151	CcSEcCtD
Nilotinib—Leukopenia—Lamivudine—hepatitis B	0.000637	0.00151	CcSEcCtD
Nilotinib—Loss of consciousness—Lamivudine—hepatitis B	0.000626	0.00148	CcSEcCtD
Nilotinib—Cough—Lamivudine—hepatitis B	0.000621	0.00147	CcSEcCtD
Nilotinib—Nausea—Telbivudine—hepatitis B	0.000612	0.00145	CcSEcCtD
Nilotinib—CYP2B6—liver—hepatitis B	0.000612	0.00347	CbGeAlD
Nilotinib—Myalgia—Lamivudine—hepatitis B	0.000606	0.00144	CcSEcCtD
Nilotinib—Chest pain—Lamivudine—hepatitis B	0.000606	0.00144	CcSEcCtD
Nilotinib—Arthralgia—Lamivudine—hepatitis B	0.000606	0.00144	CcSEcCtD
Nilotinib—CYP2C9—liver—hepatitis B	0.000606	0.00343	CbGeAlD
Nilotinib—Anxiety—Lamivudine—hepatitis B	0.000604	0.00143	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—hepatitis B	0.000602	0.00143	CcSEcCtD
Nilotinib—Discomfort—Lamivudine—hepatitis B	0.000599	0.00142	CcSEcCtD
Nilotinib—Dry mouth—Lamivudine—hepatitis B	0.000593	0.00141	CcSEcCtD
Nilotinib—CYP3A4—blood—hepatitis B	0.000591	0.00335	CbGeAlD
Nilotinib—Confusional state—Lamivudine—hepatitis B	0.000586	0.00139	CcSEcCtD
Nilotinib—CYP2D6—blood—hepatitis B	0.000581	0.00329	CbGeAlD
Nilotinib—Oedema—Lamivudine—hepatitis B	0.000581	0.00138	CcSEcCtD
Nilotinib—Infection—Lamivudine—hepatitis B	0.000577	0.00137	CcSEcCtD
Nilotinib—Shock—Lamivudine—hepatitis B	0.000572	0.00136	CcSEcCtD
Nilotinib—Nervous system disorder—Lamivudine—hepatitis B	0.00057	0.00135	CcSEcCtD
Nilotinib—Thrombocytopenia—Lamivudine—hepatitis B	0.000569	0.00135	CcSEcCtD
Nilotinib—Skin disorder—Lamivudine—hepatitis B	0.000564	0.00134	CcSEcCtD
Nilotinib—Hyperhidrosis—Lamivudine—hepatitis B	0.000562	0.00133	CcSEcCtD
Nilotinib—Anorexia—Lamivudine—hepatitis B	0.000554	0.00131	CcSEcCtD
Nilotinib—Hypotension—Lamivudine—hepatitis B	0.000543	0.00129	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Lamivudine—hepatitis B	0.000529	0.00126	CcSEcCtD
Nilotinib—Insomnia—Lamivudine—hepatitis B	0.000525	0.00125	CcSEcCtD
Nilotinib—Paraesthesia—Lamivudine—hepatitis B	0.000522	0.00124	CcSEcCtD
Nilotinib—Dyspnoea—Lamivudine—hepatitis B	0.000518	0.00123	CcSEcCtD
Nilotinib—Dyspepsia—Lamivudine—hepatitis B	0.000511	0.00121	CcSEcCtD
Nilotinib—Decreased appetite—Lamivudine—hepatitis B	0.000505	0.0012	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Lamivudine—hepatitis B	0.000502	0.00119	CcSEcCtD
Nilotinib—Fatigue—Lamivudine—hepatitis B	0.000501	0.00119	CcSEcCtD
Nilotinib—Pain—Lamivudine—hepatitis B	0.000497	0.00118	CcSEcCtD
Nilotinib—Constipation—Lamivudine—hepatitis B	0.000497	0.00118	CcSEcCtD
Nilotinib—Feeling abnormal—Lamivudine—hepatitis B	0.000479	0.00114	CcSEcCtD
Nilotinib—Gastrointestinal pain—Lamivudine—hepatitis B	0.000475	0.00113	CcSEcCtD
Nilotinib—CYP3A4—liver—hepatitis B	0.000462	0.00262	CbGeAlD
Nilotinib—Urticaria—Lamivudine—hepatitis B	0.000462	0.00109	CcSEcCtD
Nilotinib—Body temperature increased—Lamivudine—hepatitis B	0.000459	0.00109	CcSEcCtD
Nilotinib—Abdominal pain—Lamivudine—hepatitis B	0.000459	0.00109	CcSEcCtD
Nilotinib—CYP2D6—liver—hepatitis B	0.000455	0.00258	CbGeAlD
Nilotinib—Hypersensitivity—Lamivudine—hepatitis B	0.000428	0.00101	CcSEcCtD
Nilotinib—ABCB1—blood—hepatitis B	0.000418	0.00237	CbGeAlD
Nilotinib—Asthenia—Lamivudine—hepatitis B	0.000417	0.000988	CcSEcCtD
Nilotinib—Pruritus—Lamivudine—hepatitis B	0.000411	0.000975	CcSEcCtD
Nilotinib—Diarrhoea—Lamivudine—hepatitis B	0.000397	0.000942	CcSEcCtD
Nilotinib—Dizziness—Lamivudine—hepatitis B	0.000384	0.000911	CcSEcCtD
Nilotinib—Vomiting—Lamivudine—hepatitis B	0.000369	0.000876	CcSEcCtD
Nilotinib—Rash—Lamivudine—hepatitis B	0.000366	0.000869	CcSEcCtD
Nilotinib—Dermatitis—Lamivudine—hepatitis B	0.000366	0.000868	CcSEcCtD
Nilotinib—Headache—Lamivudine—hepatitis B	0.000364	0.000863	CcSEcCtD
Nilotinib—Nausea—Lamivudine—hepatitis B	0.000345	0.000818	CcSEcCtD
Nilotinib—ABCB1—liver—hepatitis B	0.000327	0.00185	CbGeAlD
Nilotinib—LCK—Adaptive Immune System—NFKB1—hepatitis B	1.85e-05	4.82e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—TLR4—hepatitis B	1.84e-05	4.82e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—F2—hepatitis B	1.84e-05	4.81e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—HLA-DRB1—hepatitis B	1.84e-05	4.81e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—CDKN1A—hepatitis B	1.83e-05	4.77e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—PTEN—hepatitis B	1.82e-05	4.76e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—NFKB1—hepatitis B	1.81e-05	4.74e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD4—hepatitis B	1.8e-05	4.7e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—TP53—hepatitis B	1.79e-05	4.67e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TGFB1—hepatitis B	1.78e-05	4.65e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—TP53—hepatitis B	1.78e-05	4.65e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GOT2—hepatitis B	1.76e-05	4.61e-05	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—IL6—hepatitis B	1.76e-05	4.61e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—CD4—hepatitis B	1.75e-05	4.58e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL2—hepatitis B	1.75e-05	4.56e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCL10—hepatitis B	1.72e-05	4.51e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—CTNNB1—hepatitis B	1.71e-05	4.47e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—TP53—hepatitis B	1.69e-05	4.42e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—CTNNB1—hepatitis B	1.69e-05	4.41e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—F2—hepatitis B	1.68e-05	4.38e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IFNG—hepatitis B	1.68e-05	4.38e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—hepatitis B	1.67e-05	4.37e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—CDKN1A—hepatitis B	1.67e-05	4.37e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—IL6—hepatitis B	1.67e-05	4.36e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—PTEN—hepatitis B	1.67e-05	4.36e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—PTEN—hepatitis B	1.67e-05	4.36e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCR5—hepatitis B	1.67e-05	4.36e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—IL6—hepatitis B	1.67e-05	4.35e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CD4—hepatitis B	1.66e-05	4.34e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—IL6—hepatitis B	1.66e-05	4.33e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL2—hepatitis B	1.65e-05	4.32e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CYP2A6—hepatitis B	1.65e-05	4.31e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—CDKN1A—hepatitis B	1.65e-05	4.3e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—PTEN—hepatitis B	1.64e-05	4.29e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IFNG—hepatitis B	1.64e-05	4.29e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—NFKB1—hepatitis B	1.64e-05	4.27e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IFNG—hepatitis B	1.63e-05	4.27e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCR5—hepatitis B	1.63e-05	4.26e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—NOS2—hepatitis B	1.62e-05	4.23e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD4—hepatitis B	1.62e-05	4.23e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CTNNB1—hepatitis B	1.6e-05	4.17e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—F2—hepatitis B	1.59e-05	4.15e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD4—hepatitis B	1.58e-05	4.14e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—IL6—hepatitis B	1.58e-05	4.13e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD4—hepatitis B	1.58e-05	4.12e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—IL6—hepatitis B	1.58e-05	4.12e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL2—hepatitis B	1.57e-05	4.11e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CDKN1A—hepatitis B	1.56e-05	4.07e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—CTNNB1—hepatitis B	1.56e-05	4.07e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IFNG—hepatitis B	1.56e-05	4.07e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—PTEN—hepatitis B	1.56e-05	4.07e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—NFKB1—hepatitis B	1.55e-05	4.05e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCR5—hepatitis B	1.55e-05	4.04e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—hepatitis B	1.54e-05	4.02e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKR1B1—hepatitis B	1.52e-05	3.98e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GOT1—hepatitis B	1.52e-05	3.98e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GGT1—hepatitis B	1.52e-05	3.98e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—CDKN1A—hepatitis B	1.52e-05	3.97e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CTNNB1—hepatitis B	1.52e-05	3.97e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—PTEN—hepatitis B	1.52e-05	3.97e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—IL6—hepatitis B	1.5e-05	3.93e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD4—hepatitis B	1.5e-05	3.93e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CD4—hepatitis B	1.49e-05	3.91e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL2—hepatitis B	1.49e-05	3.91e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GOT2—hepatitis B	1.49e-05	3.9e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL2—hepatitis B	1.49e-05	3.89e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CDKN1A—hepatitis B	1.48e-05	3.87e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—PTEN—hepatitis B	1.48e-05	3.86e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CTNNB1—hepatitis B	1.47e-05	3.85e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—NFKB1—hepatitis B	1.47e-05	3.85e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—IL6—hepatitis B	1.47e-05	3.85e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—IL6—hepatitis B	1.46e-05	3.83e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TP53—hepatitis B	1.46e-05	3.83e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GGT2—hepatitis B	1.46e-05	3.82e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL2—hepatitis B	1.46e-05	3.81e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—IL6—hepatitis B	1.46e-05	3.81e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL2—hepatitis B	1.45e-05	3.79e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CTNNB1—hepatitis B	1.44e-05	3.77e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CDKN1A—hepatitis B	1.44e-05	3.76e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CTNNB1—hepatitis B	1.44e-05	3.76e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CYP2A6—hepatitis B	1.44e-05	3.76e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PTEN—hepatitis B	1.44e-05	3.75e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—F2—hepatitis B	1.43e-05	3.74e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL6—hepatitis B	1.43e-05	3.73e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL6—hepatitis B	1.43e-05	3.73e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL6—hepatitis B	1.42e-05	3.72e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CDKN1A—hepatitis B	1.41e-05	3.68e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CTNNB1—hepatitis B	1.41e-05	3.68e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—PTEN—hepatitis B	1.41e-05	3.67e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CDKN1A—hepatitis B	1.4e-05	3.67e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—PTEN—hepatitis B	1.4e-05	3.66e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CTNNB1—hepatitis B	1.4e-05	3.66e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—F2—hepatitis B	1.4e-05	3.66e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—NFKB1—hepatitis B	1.4e-05	3.66e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—IL6—hepatitis B	1.4e-05	3.65e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—NFKB1—hepatitis B	1.39e-05	3.64e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL2—hepatitis B	1.38e-05	3.61e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—TGFB1—hepatitis B	1.38e-05	3.61e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CDKN1A—hepatitis B	1.38e-05	3.59e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—PTEN—hepatitis B	1.37e-05	3.59e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CDKN1A—hepatitis B	1.37e-05	3.58e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—PTEN—hepatitis B	1.37e-05	3.57e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—NFKB1—hepatitis B	1.37e-05	3.57e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—NFKB1—hepatitis B	1.36e-05	3.55e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CYP2A6—hepatitis B	1.35e-05	3.54e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IFNG—hepatitis B	1.35e-05	3.52e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CYP2A6—hepatitis B	1.34e-05	3.51e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCR5—hepatitis B	1.34e-05	3.5e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CTNNB1—hepatitis B	1.33e-05	3.49e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CTNNB1—hepatitis B	1.33e-05	3.47e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—F2—hepatitis B	1.33e-05	3.47e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CDKN1A—hepatitis B	1.3e-05	3.41e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—ALB—hepatitis B	1.3e-05	3.4e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—PTEN—hepatitis B	1.3e-05	3.4e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GOT2—hepatitis B	1.3e-05	3.4e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD4—hepatitis B	1.3e-05	3.4e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CDKN1A—hepatitis B	1.3e-05	3.39e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—NFKB1—hepatitis B	1.29e-05	3.38e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PTEN—hepatitis B	1.29e-05	3.38e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GOT1—hepatitis B	1.29e-05	3.37e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GGT1—hepatitis B	1.29e-05	3.37e-05	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—ALB—hepatitis B	1.27e-05	3.33e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—TGFB1—hepatitis B	1.26e-05	3.29e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL2—hepatitis B	1.25e-05	3.27e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hepatitis B	1.25e-05	3.27e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL2—hepatitis B	1.24e-05	3.24e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TGFB1—hepatitis B	1.23e-05	3.2e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GOT2—hepatitis B	1.23e-05	3.2e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GOT2—hepatitis B	1.21e-05	3.17e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CTNNB1—hepatitis B	1.21e-05	3.16e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—IL6—hepatitis B	1.21e-05	3.15e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CD4—hepatitis B	1.2e-05	3.13e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CTNNB1—hepatitis B	1.2e-05	3.13e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL2—hepatitis B	1.2e-05	3.12e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—TGFB1—hepatitis B	1.19e-05	3.11e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CDKN1A—hepatitis B	1.18e-05	3.09e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PTEN—hepatitis B	1.18e-05	3.08e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	1.17e-05	3.07e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NFKB1—hepatitis B	1.17e-05	3.06e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CDKN1A—hepatitis B	1.17e-05	3.06e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PTEN—hepatitis B	1.17e-05	3.05e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TGFB1—hepatitis B	1.17e-05	3.05e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NFKB1—hepatitis B	1.16e-05	3.04e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CTNNB1—hepatitis B	1.15e-05	3.02e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—F2—hepatitis B	1.15e-05	3e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL6—hepatitis B	1.14e-05	2.98e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL2—hepatitis B	1.13e-05	2.95e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CDKN1A—hepatitis B	1.13e-05	2.95e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—PTEN—hepatitis B	1.12e-05	2.94e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GGT1—hepatitis B	1.12e-05	2.93e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GOT1—hepatitis B	1.12e-05	2.93e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—NFKB1—hepatitis B	1.12e-05	2.93e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—ALB—hepatitis B	1.1e-05	2.89e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CTNNB1—hepatitis B	1.09e-05	2.85e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—TGFB1—hepatitis B	1.07e-05	2.8e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL2—hepatitis B	1.07e-05	2.79e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CTNNB1—hepatitis B	1.07e-05	2.78e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CDKN1A—hepatitis B	1.06e-05	2.78e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PTEN—hepatitis B	1.06e-05	2.78e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GOT1—hepatitis B	1.06e-05	2.76e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GGT1—hepatitis B	1.06e-05	2.76e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NFKB1—hepatitis B	1.06e-05	2.76e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GOT1—hepatitis B	1.05e-05	2.74e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GGT1—hepatitis B	1.05e-05	2.74e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—IL6—hepatitis B	1.04e-05	2.72e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CDKN1A—hepatitis B	1.04e-05	2.72e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PTEN—hepatitis B	1.04e-05	2.71e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CTNNB1—hepatitis B	1.03e-05	2.7e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL6—hepatitis B	1.03e-05	2.68e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—hepatitis B	1.01e-05	2.64e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CDKN1A—hepatitis B	1.01e-05	2.63e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PTEN—hepatitis B	1.01e-05	2.63e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NFKB1—hepatitis B	1e-05	2.62e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTEN—hepatitis B	9.93e-06	2.59e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TGFB1—hepatitis B	9.77e-06	2.55e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL6—hepatitis B	9.72e-06	2.54e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TGFB1—hepatitis B	9.68e-06	2.53e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL2—hepatitis B	9.63e-06	2.52e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—hepatitis B	9.6e-06	2.51e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	9.55e-06	2.5e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—IL6—hepatitis B	9.48e-06	2.48e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL2—hepatitis B	9.43e-06	2.46e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CTNNB1—hepatitis B	9.3e-06	2.43e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—hepatitis B	9.24e-06	2.41e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CTNNB1—hepatitis B	9.1e-06	2.38e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CDKN1A—hepatitis B	9.08e-06	2.37e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PTEN—hepatitis B	9.06e-06	2.37e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NFKB1—hepatitis B	9.02e-06	2.36e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—hepatitis B	8.97e-06	2.34e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2—hepatitis B	8.94e-06	2.34e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CDKN1A—hepatitis B	8.89e-06	2.32e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PTEN—hepatitis B	8.87e-06	2.32e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP2A6—hepatitis B	8.86e-06	2.31e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NFKB1—hepatitis B	8.83e-06	2.31e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TGFB1—hepatitis B	8.81e-06	2.3e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—hepatitis B	8.78e-06	2.3e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—hepatitis B	8.75e-06	2.29e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CTNNB1—hepatitis B	8.63e-06	2.25e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—TGFB1—hepatitis B	8.61e-06	2.25e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—hepatitis B	8.57e-06	2.24e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—hepatitis B	8.53e-06	2.23e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CDKN1A—hepatitis B	8.43e-06	2.2e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTEN—hepatitis B	8.42e-06	2.2e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PTEN—hepatitis B	8.41e-06	2.2e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NFKB1—hepatitis B	8.37e-06	2.19e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TGFB1—hepatitis B	8.34e-06	2.18e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—hepatitis B	8.13e-06	2.12e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—ALB—hepatitis B	8.09e-06	2.12e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—hepatitis B	8.08e-06	2.11e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—hepatitis B	8.04e-06	2.1e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GOT2—hepatitis B	8.01e-06	2.09e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—hepatitis B	7.97e-06	2.08e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2—hepatitis B	7.73e-06	2.02e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TGFB1—hepatitis B	7.51e-06	1.96e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CTNNB1—hepatitis B	7.46e-06	1.95e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—hepatitis B	7.36e-06	1.92e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TGFB1—hepatitis B	7.35e-06	1.92e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—hepatitis B	7.29e-06	1.91e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDKN1A—hepatitis B	7.29e-06	1.9e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PTEN—hepatitis B	7.27e-06	1.9e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—hepatitis B	7.25e-06	1.9e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NFKB1—hepatitis B	7.24e-06	1.89e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—hepatitis B	7.03e-06	1.84e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TGFB1—hepatitis B	6.97e-06	1.82e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GGT1—hepatitis B	6.91e-06	1.81e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GOT1—hepatitis B	6.91e-06	1.81e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—hepatitis B	6.86e-06	1.79e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—ALB—hepatitis B	6.85e-06	1.79e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—hepatitis B	6.64e-06	1.73e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—hepatitis B	6.49e-06	1.7e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—hepatitis B	6.28e-06	1.64e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—hepatitis B	6.18e-06	1.62e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTEN—hepatitis B	6.18e-06	1.61e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—hepatitis B	6.05e-06	1.58e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TGFB1—hepatitis B	6.03e-06	1.58e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ALB—hepatitis B	5.97e-06	1.56e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—hepatitis B	5.74e-06	1.5e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—hepatitis B	5.66e-06	1.48e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ALB—hepatitis B	5.63e-06	1.47e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ALB—hepatitis B	5.58e-06	1.46e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—hepatitis B	5.54e-06	1.45e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—hepatitis B	5.25e-06	1.37e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTEN—hepatitis B	5.23e-06	1.37e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—hepatitis B	4.96e-06	1.3e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTEN—hepatitis B	4.55e-06	1.19e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—hepatitis B	4.54e-06	1.19e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTEN—hepatitis B	4.29e-06	1.12e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTEN—hepatitis B	4.26e-06	1.11e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALB—hepatitis B	3.68e-06	9.61e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTEN—hepatitis B	2.81e-06	7.33e-06	CbGpPWpGaD
